Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Scleroderma Therapeutics Market

Scleroderma Therapeutics Market Size, Share & Trends Analysis Report, By Disease Type (Localized Scleroderma, Systemic Scleroderma), By Treatment Type (Immunosuppressants, Biologics, Anti-fibrotic Agents, Vasodilators, Proton Pump Inhibitors), Forecast Period (2026–2035)

Published: Jul 2026 | Report Code: OMR2022168 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Scleroderma therapeutics market was valued at $2.6 billion in 2025 and is projected to reach $4.4 billion by 2035, expanding at a CAGR of 5.2% during the forecast period (2026–2035). The market growth is primarily driven by the increasing prevalence of autoimmune diseases and the rising burden of rare chronic disorders globally. According to the World Health Organization, rare diseases affect nearly 300 million people globally, emphasizing the growing need for specialized therapeutics.

Scleroderma, also known as systemic sclerosis, involves immune dysfunction, vascular damage, and fibrosis, creating a strong demand for long-term treatment solutions such as biologics, immunosuppressants, and anti-fibrotic agents. Additionally, advancements in precision medicine and increasing clinical research activities are accelerating therapeutic innovations. Government initiatives supporting rare disease management and regulatory incentives for orphan drug development are further enhancing market expansion. The integration of advanced biologics and targeted therapies is expected to transform treatment outcomes, making the scleroderma therapeutics market a key segment within the global autoimmune disease industry.

Market Dynamics

Rising Prevalence of Rare Autoimmune Diseases Driving Market Growth

The increasing prevalence of autoimmune diseases is a significant driver for the scleroderma therapeutics market. According to the National Institutes of Health, autoimmune diseases affect approximately 23.5 million people in the United States alone, indicating a substantial patient base requiring long-term treatment. Furthermore, data from the European Commission highlights that rare diseases impact around 30 million people across Europe.

The rising awareness and early diagnosis of systemic sclerosis are boosting treatment demand, particularly for biologics and targeted therapies. Pharmaceutical companies are increasingly investing in R&D to develop disease-modifying drugs. Between 2025 and 2026, companies such as Boehringer Ingelheim and GlaxoSmithKline plc are expanding their clinical pipelines to address fibrosis-related conditions. Additionally, regulatory agencies such as the U.S. Food and Drug Administration are accelerating orphan drug approvals, enhancing market entry opportunities. These combined factors are significantly contributing to the expansion of the global scleroderma therapeutics market.

High Treatment Costs and Limited Disease Awareness Restraining Growth

Despite promising growth, the scleroderma therapeutics market faces several challenges, including high treatment costs and limited awareness. Advanced therapies such as biologics and anti-fibrotic agents are expensive, creating affordability barriers, particularly in developing regions. According to the World Health Organization, healthcare expenditure disparities continue to limit access to innovative treatments in low- and middle-income countries.  Additionally, delayed diagnosis due to the rarity and complexity of the disease leads to reduced treatment effectiveness. The lack of standardized treatment protocols and the limited availability of specialists further complicate disease management.

Supply chain constraints and regulatory complexities also affect drug availability and market penetration. However, companies are responding with strategic initiatives such as patient assistance programs, partnerships with healthcare providers, and increased investment in biosimilars to reduce costs. These innovation-driven approaches are expected to mitigate market challenges over the forecast period.

Market Segmentation

  • Based on the disease type, the market is segmented into localized scleroderma and systemic scleroderma.
  • Based on the treatment type, the market is segmented into immunosuppressants, biologics, anti-fibrotic agents, vasodilators, and proton pump inhibitors (PPIs).

Systemic Scleroderma Segment Leads the Market

Systemic scleroderma dominates the global scleroderma therapeutics market due to its severe clinical manifestations and multi-organ involvement. The condition requires comprehensive treatment approaches, including immunosuppressants and biologics, driving higher healthcare spending. Increased diagnosis rates and improved awareness are further supporting segment growth. Between 2022 and 2026, pharmaceutical companies have intensified research efforts targeting systemic sclerosis-associated complications such as interstitial lung disease (ILD). Companies like F. Hoffmann-La Roche Ltd and Johnson & Johnson are focusing on precision therapies to improve patient outcomes. The growing demand for advanced therapeutics and long-term disease management solutions continues to reinforce the dominance of this segment.

Biologics Segment to Record Strong Growth

The biologics segment is expected to witness the fastest growth during the forecast period due to increasing adoption of targeted therapies. Biologics offer improved efficacy by directly targeting immune pathways involved in fibrosis and inflammation, making them highly effective for systemic sclerosis treatment. Technological advancements in monoclonal antibodies and personalized medicine are driving innovation in this segment. Pharmaceutical companies are investing heavily in biologics R&D to develop next-generation therapies with fewer side effects. Additionally, rising clinical trial activities and regulatory support for orphan drugs are accelerating product approvals. Increasing healthcare investments and growing demand for precision medicine are expected to further boost the biologics segment growth in the coming years.

Regional Outlook

The global scleroderma therapeutics market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the scleroderma therapeutics market due to advanced healthcare infrastructure and strong pharmaceutical R&D capabilities. According to the Pharmaceutical Research and Manufacturers of America, the U.S. biopharmaceutical industry invests over $850 billion annually in research and development, supporting innovation in rare disease treatments. Additionally, favourable regulatory frameworks and orphan drug incentives provided by the U.S. Food and Drug Administration are accelerating drug approvals. The high prevalence of autoimmune diseases and increasing healthcare expenditure further contribute to market growth in the country.

India to Record Strong Growth

India is expected to witness significant growth in the scleroderma therapeutics market due to expanding healthcare infrastructure and increasing government support. According to the World Health Organization, India is strengthening its healthcare system to improve access to rare disease treatments. The implementation of the National Policy for Rare Diseases (2023) is enhancing treatment accessibility through financial support programs. Additionally, the growing pharmaceutical manufacturing sector and increasing investments in biologics production are boosting market expansion. Rising awareness and improved diagnosis rates are also contributing to strong growth prospects in the country.

Market Player Outlook

The scleroderma therapeutics market is highly competitive, characterized by the presence of leading pharmaceutical companies focusing on innovation and strategic collaborations. Companies such as Boehringer Ingelheim, F. Hoffmann-La Roche Ltd, United Therapeutics Corporation, Johnson & Johnson, and GlaxoSmithKline plc are focusing on expanding their product portfolios and strengthening their global presence. These companies are investing in biologics, anti-fibrotic agents, and precision medicine to gain a competitive edge. Strategic partnerships, acquisitions, and clinical advancements are key strategies shaping the competitive landscape.

Recent Developments

  • In June 2024, Johnson & Johnson strengthened its position in the scleroderma therapeutics space through the advancement of Nipocalimab, an FcRn-blocking monoclonal antibody demonstrating strong Phase 3 efficacy in autoantibody-driven diseases. The therapy showed sustained disease control and significant improvement in daily living outcomes, highlighting its potential to address unmet needs across immune-mediated conditions.
  • In October 2023, Boehringer Ingelheim partnered with the Scleroderma Research Foundation to advance scleroderma therapeutics through the innovative CONQUEST trial platform, focusing initially on interstitial lung disease linked to the condition. This collaboration, alongside earlier involvement from Sanofi, aims to accelerate clinical development by enabling multi-therapy evaluation under a unified trial structure.

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global scleroderma therapeutics market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.
  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Scleroderma Therapeutics Market Sales Analysis – Disease Type | Treatment Type ($ Million)
  • Global Scleroderma Therapeutics Market Sales Performance of Top Countries

1.1 Research Methodology

  • Primary Research Approach
  • Secondary Research Approach

1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

2.2.1 Key Scleroderma Therapeutics Market Trends

2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Scleroderma Therapeutics Market

2.3.1 Competitive Rivalry

2.3.2 Threat of New Entrants

2.3.3 Bargaining Power of Suppliers

2.3.4 Bargaining Power of Buyers

2.3.5 Threat of Substitutes

  1. Market Determinants

3.1 Market Drivers

3.1.1 Drivers For Global Scleroderma Therapeutics Market: Impact Analysis

3.2 Market Pain Points and Challenges

3.2.1 Restraints For Global Scleroderma Therapeutics Market: Impact Analysis

3.3 Market Opportunities

3.3.1 Opportunities For Global Scleroderma Therapeutics Market: Impact Analysis

  1. Competitive Landscape

4.1 Competitive Dashboard – Scleroderma Therapeutics Market Revenue and Share by Manufacturers

  • Scleroderma Therapeutics Product Comparison Analysis
  • Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 Boehringer Ingelheim

4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy

4.2.2 F. Hoffmann-La Roche Ltd (Genentech)

4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy

4.2.3 United Therapeutics Corporation

4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy

4.2.4 Johnson & Johnson (Janssen Pharmaceuticals)

4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy

4.2.5 GlaxoSmithKline plc (GSK)

4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

4.3.1 Merger and Acquisition

4.3.2 Product Launch

4.3.3 Partnership And Collaboration

  1. Global Scleroderma Therapeutics Market Sales Analysis by Disease Type ($ Million)

5.1 Localized Scleroderma

5.2 Systemic Scleroderma

  1. Global Scleroderma Therapeutics Market Sales Analysis by Treatment Type ($ Million)

6.1 Immunosuppressants

6.2 Biologics

6.3 Anti-fibrotic Agents

6.4 Vasodilators

6.5 Proton Pump Inhibitors (PPIs)

  1. Regional Analysis

7.1 North American Scleroderma Therapeutics Market Sales Analysis – Disease Type | Treatment Type | Country ($ Million)

7.1.1 United States

7.1.2 Canada

7.2 European Scleroderma Therapeutics Market Sales Analysis – Disease Type | Treatment Type | Country ($ Million)

7.2.1 UK

7.2.2 Germany

7.2.3 Italy

7.2.4 Spain

7.2.5 France

7.2.6 Russia

7.2.7 Rest of Europe

7.3 Asia-Pacific Scleroderma Therapeutics Market Sales Analysis – Disease Type | Treatment Type | Country ($ Million)

7.3.1 China

7.3.2 Japan

7.3.3 South Korea

7.3.4 India

7.3.5 Australia & New Zealand

7.3.6 ASEAN Countries

7.3.7 Rest of Asia-Pacific

7.4 Rest of the World Scleroderma Therapeutics Market Sales Analysis – Disease Type | Treatment Type | Country ($ Million)

7.4.1 Latin America

7.4.2 Middle East and Africa

  1. Company Profiles

8.1 AbbVie Inc.

8.1.1 Quick Facts

8.1.2 Company Overview

8.1.3 Product Portfolio

8.1.4 Business Strategies

8.2 Accord Healthcare (Intas Pharmaceuticals)

8.2.1 Quick Facts

8.2.2 Company Overview

8.2.3 Product Portfolio

8.2.4 Business Strategies

8.3 Apotex Inc.

8.3.1 Quick Facts

8.3.2 Company Overview

8.3.3 Product Portfolio

8.3.4 Business Strategies

8.4 AstraZeneca plc

8.4.1 Quick Facts

8.4.2 Company Overview

8.4.3 Product Portfolio

8.4.4 Business Strategies

8.5 Bayer AG

8.5.1 Quick Facts

8.5.2 Company Overview

8.5.3 Product Portfolio

8.5.4 Business Strategies

8.6 Boehringer Ingelheim International GmbH

8.6.1 Quick Facts

8.6.2 Company Overview

8.6.3 Product Portfolio

8.6.4 Business Strategies

8.7 Bristol Myers Squibb (Celgene)

8.7.1 Quick Facts

8.7.2 Company Overview

8.7.3 Product Portfolio

8.7.4 Business Strategies

8.8 Dr. Reddy’s Laboratories

8.8.1 Quick Facts

8.8.2 Company Overview

8.8.3 Product Portfolio

8.8.4 Business Strategies

8.9 Eli Lilly and Company

8.9.1 Quick Facts

8.9.2 Company Overview

8.9.3 Product Portfolio

8.9.4 Business Strategies

8.10 F. Hoffmann-La Roche Ltd (Genentech)

8.10.1 Quick Facts

8.10.2 Company Overview

8.10.3 Product Portfolio

8.10.4 Business Strategies

8.11 Fresenius Kabi AG

8.11.1 Quick Facts

8.11.2 Company Overview

8.11.3 Product Portfolio

8.11.4 Business Strategies

8.12 GlaxoSmithKline plc (GSK)

8.12.1 Quick Facts

8.12.2 Company Overview

8.12.3 Product Portfolio

8.12.4 Business Strategies

8.13 Hikma Pharmaceuticals PLC

8.13.1 Quick Facts

8.13.2 Company Overview

8.13.3 Product Portfolio

8.13.4 Business Strategies

8.14 Horizon Therapeutics (Amgen)

8.14.1 Quick Facts

8.14.2 Company Overview

8.14.3 Product Portfolio

8.14.4 Business Strategies

8.15 JAMP Pharma Group

8.15.1 Quick Facts

8.15.2 Company Overview

8.15.3 Product Portfolio

8.15.4 Business Strategies

8.16 Johnson & Johnson (Janssen Pharmaceuticals)

8.16.1 Quick Facts

8.16.2 Company Overview

8.16.3 Product Portfolio

8.16.4 Business Strategies

8.17 Lupin Limited

8.17.1 Quick Facts

8.17.2 Company Overview

8.17.3 Product Portfolio

8.17.4 Business Strategies

8.18 Novartis AG (Sandoz)

8.18.1 Quick Facts

8.18.2 Company Overview

8.18.3 Product Portfolio

8.18.4 Business Strategies

8.19 Pfizer Inc.

8.19.1 Quick Facts

8.19.2 Company Overview

8.19.3 Product Portfolio

8.19.4 Business Strategies

8.20 Sanofi S.A.

8.20.1 Quick Facts

8.20.2 Company Overview

8.20.3 Product Portfolio

8.20.4 Business Strategies

1. Global Scleroderma Therapeutics Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

2. Global Localized Scleroderma Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)

3. Global Systemic Scleroderma Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)

4. Global Scleroderma Therapeutics Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

5. Global Immunosuppressants Scleroderma Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)

6. Global Biologics Scleroderma Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)

7. Global Anti-fibrotic Agents Scleroderma Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)

8. Global Vasodilators Scleroderma Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)

9. Global Proton Pump Inhibitors (PPIs) Scleroderma Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)

10. Global Scleroderma Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)

11. North America Scleroderma Therapeutics Market Research and Analysis by Country, 2025–2035 ($ Million)

12. North America Scleroderma Therapeutics Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

13. North America Scleroderma Therapeutics Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

14. Europe Scleroderma Therapeutics Market Research and Analysis by Country, 2025–2035 ($ Million)

15. Europe Scleroderma Therapeutics Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

16. Europe Scleroderma Therapeutics Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

17. Asia-Pacific Scleroderma Therapeutics Market Research and Analysis by Country, 2025–2035 ($ Million)

18. Asia-Pacific Scleroderma Therapeutics Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

19. Asia-Pacific Scleroderma Therapeutics Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

20. Rest of the World Scleroderma Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)

21. Rest of the World Scleroderma Therapeutics Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

22. Rest of the World Scleroderma Therapeutics Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

1. Global Scleroderma Therapeutics Market Share by Disease Type, 2025 vs 2035 (%)

2. Global Localized Scleroderma Therapeutics Market Research and Analysis by Region, 2025 vs 2035 (%)

3. Global Systemic Scleroderma Therapeutics Market Research and Analysis by Region, 2025 vs 2035 (%)

4. Global Scleroderma Therapeutics Market Share by Treatment Type, 2025 vs 2035 (%)

5. Global Immunosuppressants Scleroderma Therapeutics Market Research and Analysis by Region, 2025 vs 2035 (%)

6. Global Biologics Scleroderma Therapeutics Market Research and Analysis by Region, 2025 vs 2035 (%)

7. Global Anti-fibrotic Agents Scleroderma Therapeutics Market Research and Analysis by Region, 2025 Vs 2035 (%)

8. Global Vasodilators Scleroderma Therapeutics Market Research and Analysis by Region, 2025 vs 2035 (%)

9. Global Proton Pump Inhibitors (PPIs) Scleroderma Therapeutics Market Research and Analysis by Region, 2025 Vs 2035 (%)

10. Global Scleroderma Therapeutics Market Share by Region, 2025 vs 2035 (%)

11. United States Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

12. Canada Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

13. UK Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

14. France Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

15. Germany Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

16. Italy Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

17. Spain Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

18. Russia Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

19. India Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

20. China Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

21. Japan Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

22. South Korea Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

23. Australia & New Zealand Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

24. ASEAN Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

25. Rest of Asia-Pacific Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

26. Latin America Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

27. Middle East & Africa Scleroderma Therapeutics Market Size, 2025-2035 ($ Million)

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The market was valued at $2.6 billion in 2025 and is projected to reach $4.5 billion by 2035.
The market is expected to grow at a CAGR of 5.2% during 2026 to 2035.
The systemic scleroderma segment dominates due to its severity and higher treatment demand.
North America, particularly the United States, leads due to strong R&D and healthcare infrastructure.
The biologics segment is expected to grow the fastest due to advancements in targeted therapies.